Search | IOVS | ARVO Journals

iovs

Issues
Topics
For Authors
About
- Editorial Board
- Subscriptions

Journals Home

SIGN IN

Forgot password?

Create an Account

To View More...

Purchase this article with an account.

or

Subscribe Now

Issues
Topics
For Authors
About
- Editorial Board
- Subscriptions

Narrow View

NARROW

Content Type

Meeting Abstract (12)
Journal Articles (2)

Journal

Investigative Ophthalmology & Visual Science (14)

Article Type

ARVO Annual Meeting Abstract (12)
Cornea (1)
Retinal Cell Biology (1)

Topics

Eye Anatomy and Disorders (2)
Cornea (1)
Retina (1)
Retinal Cell Biology (1)

Tags

brain-derived neurotrophic factor (1)
ciliary neurotrophic factor (1)
cornea (1)
dehydration (1)
electroretinography (1)
eye (1)
nerve growth factors (1)
optical coherence tomography (1)
oryctolagus cuniculus (1)
photochemotherapy (1)

Specify Date Range

From: To: Apply

Showing 1 – 14 of 14

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2017

The Ocular Safety, Tolerability, and Efficacy of Once Daily and Twice Daily 0.075% Bromfenac Ophthalmic Solution (Formulated in DuraSite ® ) in Patients Post Cataract Surgery

Afshin Shafiee; Judith Hutcheson; Lyle Bowman; Kamran Hosseini

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1822. doi:

ARVO Annual Meeting Abstract June 2015

A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Fixed Combination of Azithromycin and Dexamethasone in DuraSite, and Dexamethasone alone in DuraSite in the Treatment of Blepharitis

Kamran Hosseini; Richard Lindstrom

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3058. doi:

ARVO Annual Meeting Abstract April 2014

Accurate Dose Delivery by Subconjunctival Jet Injection Device with Zero Back Flow

Gholam A Peyman; Michel Cormier; Richard Lindstrom; Kamran Hosseini

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):479. doi:

ARVO Annual Meeting Abstract April 2014

Clinical Response to Treatment with Topical Ocular 0.1% Dexamethasone in DuraSite® in Subjects with Blepharitis

Kamran Hosseini; Judith A Hutcheson; Lyle M Bowman

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1459. doi:

ARVO Annual Meeting Abstract April 2014

Clinical Response of 0.075% Bromfenac in DuraSite® on Ocular Inflammation and Pain Post Cataract Surgery

Judith A Hutcheson; Dragana McMullen; Kamran Hosseini

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1473. doi:

ARVO Annual Meeting Abstract June 2013

Safety of DuraSite vehicle as part of a topical treatment in cataract surgery patients

Judith Hutcheson; Lyle Bowman; Kamran Hosseini

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):1093. doi:

ARVO Annual Meeting Abstract June 2013

Ocular Pharmacokinetics of 0.2% and 0.4% Ketorolac Tromethamine Formulated in DuraSite or DuraSite 2 Delivery Systems Compared to Acular LS in Rabbits

Afshin Shafiee; Lyle Bowman; Eddie Hou; Kamran Hosseini

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):116. doi:

ARVO Annual Meeting Abstract June 2013

Aqueous humor concentration of Bromfenac 0.09% (Bromday) compared with Bromfenac in DuraSite 0.075% (Bromsite) in cataract patients undergoing phacoemulsification after 3 days dosing

Kamran Hosseini; Judith Hutcheson; Lyle Bowman

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):5061. doi:

ARVO Annual Meeting Abstract June 2013

Developing a questionnaire to measure the quality of life of Blepharitis patients

Linda Bourque; Melissa Kelley; Kamran Hosseini

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):5318. doi:

ARVO Annual Meeting Abstract June 2013

Ocular Pharmacokinetics of ISV-215 (Bimatoprost 0.03%) Formulated in a DuraSite Delivery System Compared to Lumigan in Rabbits

Lyle Bowman; Afshin Shafiee; Eddie Hou; Kamran Hosseini

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):765. doi:

ARVO Annual Meeting Abstract April 2011

Safety of Bromfenac Formulated in DuraSite on Ocular Tissues

Lyle M. Bowman; Kamran Hosseini

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):476. doi:

ARVO Annual Meeting Abstract April 2011

Clinical Response of Dexamethasone 0.1% Formulated in DuraSite on Blepharoconjunctivitis Patients

Kamran Hosseini; Judith Hutcheson; Lyle M. Bowman

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):4247. doi:

Retinal Cell Biology January 2007

Neurotrophic Factors Minimize the Retinal Toxicity of Verteporfin Photodynamic Therapy

PDF

Daniel M. Paskowitz; Kate M. Donohue-Rolfe; Haidong Yang; Douglas Yasumura; Michael T. Matthes; Kamran Hosseini; Carolyn M. Graybeal; George Nune; Marco A. Zarbin; Matthew M. LaVail; Jacque L. Duncan
TAGS: brain-derived neurotrophic factor, ciliary neurotrophic factor, electroretinography, nerve growth factors, photochemotherapy, photoreceptors, eye, retina, verteporfin, retinal toxicity
Invest. Ophthalmol. Vis. Sci.. 2007; 48(1):430-437. doi: 10.1167/iovs.06-0690

Cornea August 2004

Monitoring of Rabbit Cornea Response to Dehydration Stress by Optical Coherence Tomography

PDF

Kamran Hosseini; Alexander I. Kholodnykh; Irina Y. Petrova; Rinat O. Esenaliev; Fred Hendrikse; Massoud Motamedi
TAGS: dehydration, oryctolagus cuniculus, cornea, stress, optical coherence tomography
Invest. Ophthalmol. Vis. Sci.. 2004; 45(8):2555-2562. doi: 10.1167/iovs.03-0792

« Previous

Advertisement

Follow @ARVOiovs

IOVS Home
Issues
Topics
For Authors
About
- Editorial Board
- Subscriptions

Online ISSN: 1552-5783

Investigative Ophthalmology & Visual Science
Journal of Vision
Translational Vision Science & Technology

JOURNALS HOME
TOPICS
ABOUT ARVO JOURNALS

Copyright © 2015 Association for Research in Vision and Ophthalmology.

Forgot password?

To View More...

Purchase this article with an account.

Create an Account

or

Subscribe Now

×

×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept